Keywords: |
aged; aged, 80 and over; middle aged; survival rate; multimodality cancer therapy; note; combined modality therapy; cancer staging; follow up; follow-up studies; neoplasm staging; prostate specific antigen; metastasis; neoplasm recurrence, local; pathology; prostate-specific antigen; prostatic neoplasms; blood; prostatectomy; nomograms; tumor recurrence; prostate tumor; androgen antagonists; neoplasm metastasis; prediction and forecasting; predictive value of tests; antiandrogen; nomogram
|